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OBJECTIVE — LDL cholesterol 2.80 mmol/l was associated with increased cancer risk in
type 2 diabetes. We explored the 1) interaction between low LDL cholesterol and albuminuria
and 2) interaction between copresence of these two risk factors and statin use for cancer in type
2 diabetes.
RESEARCH DESIGN AND METHODS — We analyzed prospective data for 3,793
Chinese type 2 diabetic patients who remained naive for statin treatment and 1,483 patients in
whomstatintreatmentwasinitiatedduringamedianfollow-upperiodof5.24years.Allpatients
were free of cancer at baseline. Biological interactions were estimated using relative excess risk
duetointeraction(RERI),attributableproportionduetointeraction(AP),andsynergyindex(S).
RERI  0, AP  0, or S  1 indicates biological interaction.
RESULTS — In3,793statin-naivetype2diabeticpatients,copresenceoflowLDLcholesterol
and albuminuria increased cancer risk by 2.8-fold (hazard ratio 2.77 [95% CI 1.78–4.31]) with
signiﬁcant biological interactions (RERI 1.05 [0.04–2.06]; AP 0.38 [0.09–0.66]). In the whole
cohort of 5,276 type 2 diabetic patients, there was interaction between nonuse of statins and
copresence of low LDL cholesterol and albuminuria with increased cancer risk (RERI 2.87
[0.64–5.09]andAP0.60[0.29–0.90]).StatinnonuserswithLDLcholesterol2.80mmol/land
albumunuria had a 4.9-fold risk of cancer compared with statin users with or without both risk
factors.
CONCLUSIONS — In type 2 diabetes, there was interaction between low LDL cholesterol
and albuminuria with increased cancer risks. The latter was attenuated in the presence of statin
treatment.
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T
ype 2 diabetes predisposes patients
to a variety of cancers (1–4). The
prevalence of cancer in type 2 dia-
beticpatientsisone-thirdhigherthanthat
in the general population (5). Based on a
prospective database, we reported that
the association between LDL cholesterol
and cancer risk in type 2 diabetes was V-
shaped with a nadir at 3.28 mmol/l and
that LDL cholesterol levels 2.80 mmol/l
and 3.80 mmol/l were both associated
with elevated cancer risks (5).
Albuminuriaisanearlymanifestation
of generalized endothelial dysfunction
(6). This urinary marker is closely associ-
atedwithhyperglycemia,obesity,andhy-
pertension (7). Using a prospective
registry, we found possible biological in-
teractions between albuminuria and hy-
perglycemia with increased risk of
ischemic stroke (7). Given the intimate
relationships between albuminuria, dys-
lipidemia, and cancer risk, we asked
whether there are biological interactions
between low LDL cholesterol (2.80
mmol/l) and albuminuria for the risk of
cancer in type 2 diabetes. Given the in-
consistent ﬁndings for use of lipid-
lowering drugs and cancer risks (8–10)
and a paucity of such data in type 2 dia-
betes, we also explore the potential inter-
action (a second-order interaction)
between use of statins and copresence of
low LDL cholesterol and albuminuria on
cancer risks.
RESEARCH DESIGN AND
METHODS— The Hong Kong Diabe-
tes Registry (5,11) was established in
1995 at the Prince of Wales Hospital, the
teaching hospital of The Chinese Univer-
sity of Hong Kong. The hospital serves a
population of 1.2 million. The referral
sources of the cohort included both com-
munity and hospital clinics in the catch-
ment region. Less than 10% of the
enrolled patients had hospital admissions
within6–8weeksbeforeassessment.The
1998 World Health Organization criteria
(the 1985 criteria were used before July
1998) were used to diagnose diabetes
(12). A 4-h assessment of complications
andriskfactorswasperformedonanout-
patient basis, modiﬁed from the Euro-
pean DiabCare protocol (13). Once a
patient had undergone this comprehen-
sive assessment, he or she was considered
to have entered this study cohort and
wouldbefolloweduntilthetimeofdeath.
Ethics approval was obtained from the
ChineseUniversityofHongKongClinical
Research Ethics Committee. The Declara-
tion of Helsinki was adhered to and in-
formed consent was obtained from all
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analysis and research purposes.
The clinical end points included dis-
charge diagnoses and mortality from en-
rollment to 30 July 2005, or otherwise
censored on 30 July 2005. Details of all
clinical end points were retrieved from
the Hong Kong Hospital Authority Cen-
tral Computer System, which recorded
admissionstoallpublichospitalsinHong
Kong. Mortality data were retrieved from
the Hong Kong Death Registry and were
cross-checked with hospital discharge
status (11). We also extracted drug dis-
pensing data from the Hospital Authority
Computer System including the start
dates and end dates for each of the drugs
of interest. In Hong Kong public hospi-
tals, all medications are dispensed on site
in both inpatient and outpatient settings.
These databases were matched by a
unique identiﬁcation number, the Hong
Kong Identity Card number, which is
compulsory for all residents in Hong
Kong.
From 1996 to 2005, 7,387 diabetic
patients were enrolled in the registry. We
excluded the following patients from the
ﬁrst stage of analysis: 1) 328 patients with
type1diabetesormissingdetailsontypes
of diabetes (5), 2) 45 patients with non-
Chinese or unknown nationality, 3) 175
patientswithaknownhistoryofcanceror
receiving treatment for cancer at enroll-
ment, 4) 736 patients with missing values
for any variables included in the analysis
(see Table 3 for a list of variables), and 5)
2,310 patients who were exposed to
statins from enrollment to dates of cancer,
death,orcensoring,whichevercameﬁrst.
Thus, in the ﬁrst stage of analysis, we in-
cluded 3,793 patients who remained na-
ive for statin treatment throughout the
observational period and had complete
sets of variables for the analysis of the in-
teraction between low LDL cholesterol
and albuminuria. The reasons for these
exclusions were as follows: 1) pretreat-
ment LDL cholesterol levels of patients
treated with statins at enrollment were
unknown and 2) use of statins is a poten-
tial confounder for the risk association of
cancer with LDL cholesterol (5). Of the
2,310 patients treated with statins, in
1,483patientstherapywasstartedduring
the follow-up period. We included these
1,483 patients in the above statin-naive
cohort of 3,793 patients. In this second
stage of analysis, we tested the interaction
between use of statins and copresence of
LDL cholesterol 2.80 mmol/l and albu-
minuria in these 5,276 patients.
Clinical and laboratory
measurements
On the day of the visit, patients attended
the center after 8 h of fasting and under-
went clinical assessments and laboratory
investigationsasdescribedpreviously(5).
A sterile, random spot urinary sample
was used to measure the albumin-to-
creatinine ratio (ACR). Albuminuria was
deﬁned as ACR 2.5 mg/mmol in men
and 3.5 mg/mmol in women. The ab-
breviated Modiﬁcation of Diet in Renal
Disease Study formula recalibrated for
Chinese (14) was used to estimate glo-
merular ﬁltration rate (eGFR) expressed
in milliliters per minute per 1.73 m
2:
eGFR  186  [SCR  0.011]
1.154 
[age]
0.203  [0.742; if female] 1.233,
where SCR is serum creatinine expressed
as micromoles per liter (original milli-
grams per deciliter converted to micro-
moles per liter) and 1.233 is the adjusting
coefﬁcient for Chinese. Lipids (total cho-
lesterol, triglycerides, and HDL choles-
terol) were measured by enzymatic
methods on a Hitachi 911 automated an-
Table 1—Clinical and biochemical characteristics of the study cohort stratiﬁed according to
use of statins during follow-up period
Non–statin users Statin users P
n 3,793 1,483
Baseline variables and outcomes
Age (years) 56 (22) 58 (18) 0.0001*
Male sex 1,794 (47.3%) 676 (45.6%) 0.2619†
Smoking status 0.5662†
Ex-smoker 559 (14.7%) 231 (15.6%)
Current smoker 594 (15.7%) 242 (16.3%)
Alcohol drinking status 0.4829†
Ex-drinker 457 (12.1%) 187 (12.6%)
Current drinker 298 (7.9%) 103 (7.0%)
BMI, kg/m
2 24.6 (4.9) 25.0 (4.8) 0.0001*
Duration of diabetes (years) 5 (9) 7 (10) 0.0001*
Systolic blood pressure (mmHg) 132 (25) 138 (27) 0.0001*
Diastolic blood pressure (mmHg) 75 (14) 76 (14) 0.0001*
A1C (%) 7.0 (2.0) 7.7 (2.2) 0.0001*
LDL cholesterol (mmol/l) 2.90 (1.06) 3.71 (1.15) 0.0001*
HDL cholesterol (mmol/l) 1.27 (0.47) 1.22 (0.42) 0.0001*
Triglycerides (mmol/l) 1.21 (0.88) 1.58 (1.11) 0.0001*
Total cholesterol (mmol/l) 4.90 (1.17) 5.80 (1.30) 0.0001*
ACR (mg/mmol) 1.63 (6.03) 3.78 (25.5) 0.0001*
LDL cholesterol 2.80 mmol/l plus
albuminuria 594 (15.7%) 101 (6.8%) 0.0001†
eGFR (ml/min per 1.73 m
2) 107.2 (40.4) 99.4 (43.0) 0.0001*
Prior myocardial infarction 21 (0.6%) 31 (2.1%) 0.0001†
Prior stroke 112 (3.0%) 86 (5.8%) 0.0001†
Cancer during follow-up 210 (5.5%) 34 (2.3%) 0.0001†
Death (all-cause) during follow-up 337 (8.9%) 103 (7.0%) 0.0220†
Medications at enrollment
Fibrates 83 (2.2%) 95 (6.4%) 0.0001†
Oral antidiabetes drugs 2,402 (63.3%) 1,022 (68.9%) 0.0001†
Insulin 562 (14.8%) 350 (23.6%) 0.0001†
ACEIs or ARBs 689 (18.2%) 427 (28.8%) 0.0001†
Antihypertensive drugs other than
ACEIs or ARBs 1,270 (33.5%) 591 (39.9%) 0.0001†
Medications during follow-up period‡
Fibrates 282 (7.4%) 251 (16.9%) 0.0001†
Oral antidiabetes drugs 3,076 (81.1%) 1,343 (90.6%) 0.0001†
Insulin 1,114 (29.4%) 794 (53.5%) 0.0001†
ACEIs or ARBs 1,777 (46.9%) 1,109 (74.8%) 0.0001†
Duration of use of statins (years) — 2.07 (3.18)
Data are median (25th–75th percentiles) or n (%). Albuminuria was deﬁned as spot urinary ACR 2.5
mg/mmolinmenand3.5mg/mmolinwomen.*DerivedfromaWilcoxontwo-sampletest.†Derivedfrom
a 
2 test. ‡From baseline to cancer, death, or censoring dates whichever came ﬁrst.
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heim, Germany) using reagent kits
supplied by the manufacturer. LDL choles-
terol was calculated using the Friedewald
equation (15). The precision performance
of these assays was within the manufactur-
er’s speciﬁcations.
Deﬁnition of cancer
Hospital discharge principle diagnoses,
coded according to the ICD-9, were used
toidentifycancerevents.Theendpointof
this study was deﬁned as incident cancer
(either fatal or nonfatal; codes 140–208)
during the follow-up period.
Statistical analyses
SAS (release 9.10; SAS Institute, Cary,
NC) was used for all analyses. Cox pro-
portional hazards regression was used to
obtain hazard ratios (HRs) of incident
cancer with status of statin use, presence
of low LDL cholesterol, and albuminuria.
Follow-up time was calculated as the pe-
riod in years from the enrollment to the
date of the ﬁrst cancer event, death, or
censoring, whichever came ﬁrst.
To estimate the biological interaction
between albuminuria and low LDL cho-
lesterol (deﬁned as 2.80 mmol/l), we
created three new variables: 1) low LDL
cholesterol  yes and albuminuria  no
versus others; 2) low LDL cholesterol 
no and albuminuria  yes versus others;
and 3) low LDL cholesterol  yes and
albuminuria  yes versus others (16,17).
Wealsoexaminedthesecond-orderinter-
action between statin use and copresence
of low LDL cholesterol and albuminuria.
We created three variables using copres-
enceoflowLDLcholesterolandalbumin-
uria as one risk factor and nonuse of
statins as the other: 1) low LDL choles-
terol plus albuminuria  yes and use of
statins  yes versus others; 2) low LDL
cholesterol plus albuminuria  no and
use of statins  no versus others; and 3)
low LDL cholesterol plus albuminuria 
yes and use of statins  no versus others
(see Table 2).
We used three measures to estimate
biologicalinteractions:relativeexcessrisk
due to interaction (RERI); attributable
proportion due to interaction (AP); and
synergy index (S). The RERI is the excess
risk due to interaction relative to the risk
without exposure. AP refers to the attrib-
utable proportion of disease that is due to
interaction among persons with both ex-
posures. S is the excess risk from both
exposureswhenthereisabiologicalinter-
action, relative to the risk from both ex-
posures without interaction (18). RERI 
0, AP  0, or S  1 indicates a biological
interaction. In Cox models, the RERI is
Table 2—HRs for the risk of cancer in relation to low LDL cholesterol, albuminuria, and statin use
No. at risk HR (95% CI) P
Interaction models for albuminuria and low LDL cholesterol*
Model 1†
LDL cholesterol 2.8 mmol/l and normoalbuminuria vs. others 961 1.35 (0.89–2.07) 0.1603
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 837 1.40 (0.97–2.02) 0.0718
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 594 3.08 (2.08–4.56) 0.0001
Model 2‡
LDL cholesterol 2.8 mmol/l and normoalbuminuria vs. others 961 1.41 (0.92–2.16) 0.1129
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 837 1.16 (0.78–1.74) 0.4576
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 594 2.59 (1.69–3.96) 0.0001
Model 3§
LDL cholesterol 2.8 mmol/l and normoalbuminuria vs. others 961 1.45 (0.94–2.24) 0.0932
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 837 1.27 (0.85–1.90) 0.2435
LDL cholesterol 2.8 mmol/l and albuminuria vs. others 594 2.77 (1.78–4.31) 0.0001
Interaction models for copresence of LDL cholesterol 2.80 mmol/l plus
albuminuria and nonuse of statins
Model 1†
Low LDL cholesterol and albuminuria  yes and use of statins vs. others 101 0.63 (0.09–4.64) 0.6476
Low LDL cholesterol and albuminuria  no and nonuse of statins vs. others 3,199 2.54 (1.72–3.76) 0.0001
Low LDL cholesterol and albuminuria  yes and nonuse of statins vs. others 594 6.24 (3.86–10.07) 0.0001
Model 2‡
Low LDL cholesterol and albuminuria  yes and use of statins vs. others 101 0.67 (0.09–4.96) 0.6942
Low LDL cholesterol and albuminuria  no and nonuse of statins vs. others 3,199 2.21 (1.47–3.33) 0.0001
Low LDL cholesterol and albuminuria  yes and nonuse of statins vs. others 594 4.43 (2.72–7.21) 0.0001
Model 3§¶
Low LDL cholesterol and albuminuria  yes and use of statins vs. others 101 0.64 (0.09–4.80) 0.6645
Low LDL cholesterol and albuminuria  no and nonuse of statins vs. others 3,199 2.31 (1.51–3.91) 0.0001
Low LDL cholesterol and albuminuria  yes and nonuse of statins vs. others 594 4.81 (2.81–8.24) 0.0001
*The analysis was performed in 3,793 patients without use of statins. †Adjusted for LDL cholesterol 3.80 mmol/l. ‡Further adjusted for age, sex, BMI, smoking
status (current smoker plus ex-smoker), drinking status (current drinker plus ex-drinker), duration of diabetes, A1C, systolic blood pressure, HDL cholesterol,
triglycerides,eGFR,andmedicationsfromenrollmenttocancer,death,orcensoringdate,whichevercameﬁrst.MedicationsincludeACEIsorARBs,oralantidiabetes
drugs, insulin, ﬁbrates and other antihypertensive drugs at enrollment. §Adjusted for covariates listed in ‡, but restricted cubic spline functions were used for all the
continuous covariates. The analysis was performed in 3,793 patients without use of statins plus 1,483 patients who used statins during follow-up. ¶Stratiﬁed Cox
models including deciles of propensity scores to adjust for likelihood using statins during follow-up. The propensity score was calculated using a logistic regression
procedure with use of statins as the dependent variable and age, sex, BMI, LDL cholesterol, HDL cholesterol, triglycerides, smoking status, drinking status, A1C,
systolic blood pressure, log (ACR  1), eGFR, duration of diabetes, peripheral arterial disease, retinopathy, sensory neuropathy, prior history of myocardial
infarction, and stroke as independent variables (The c-statistic was 0.80).
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(19).
Weusedastructuredanalysisscheme
toadjustforcovariates.First,weobtained
the three biological interaction measures
after adjusting for high LDL cholesterol,
i.e., 3.8 mmol/l. Second, we adjusted
for age, sex, BMI, ever-smoking status,
ever–alcohol drinking status, duration of
diabetes, A1C, systolic blood pressure,
HDLcholesterol,triglycerides,eGFR,and
medications from enrollment to cancer,
death, or censoring dates, whichever
came ﬁrst. These drugs included ACE in-
hibitors (ACEIs), angiotensin II receptor
blockers (ARBs), oral antidiabetes drugs,
insulin, and ﬁbrates and other antihyper-
tensive drugs at enrollment. Third, be-
causelipidsareassociatedwithcancerina
V-shaped or A-shaped relation (5,20), we
usedtherestrictedcubicsplineswithfour
knots at the 5th, 35th, 65th, and 95th
percentiles of covariables to adjust for
confounding effects due to nonlinear as-
sociationsoflipidsandothercovariatesin
additional Cox models (5). To adjust for
confounding effects due to the likelihood
of drug use during follow-up period, we
calculated a propensity score for use of
statins, as described previously (21). We
thenusedstratiﬁedCoxmodelsondeciles
of the likelihood to estimate the interac-
tion of nonuse of statin and copresence of
low LDL cholesterol and albuminuria on
cancer risk. Proportionality and correla-
tions between pairs of baseline covariates
werecheckedasdescribed(5).Two-sided
P  0.05 was considered signiﬁcant.
RESULTS
Characteristics of the patients
Compared with statin-naive patients,
those in whom statin treatment was initi-
atedduringfollow-upwereolderandhad
a longer duration of diabetes and poorer
metabolic proﬁle. During a median
(25th–75th percentiles) follow-up period
of 5.24 (2.99–7.10) and a mean  SD
follow-up period of 5.01  2.36 years,
the statin users were more likely to use
other drugs and develop cardiovascular
complications but less likely to have can-
cer and die (Table 1).
Among 3,793 patients never exposed
to statins, 210 patients developed cancer
during a median of 5.08 (interquartile
range 2.84–7.07) years of follow-up with
an incidence of 11.27 (95% CI 9.76–
12.79) per 1,000 person-years. Patients
who developed cancer were older, had
higher systolic blood pressure and ACR
and lower eGFR, and were more likely to
use tobacco, alcohol, and antihyperten-
sive drugs (except for ACEIs or ARBs)
than patients without cancer (supple-
mentary Table, available in an online ap-
pendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-0725/DC1).
Biological interaction of low LDL
cholesterol and albuminuria for
cancer
Copresence of LDL cholesterol 2.80
mmol/l and albuminuria was associated
with a 3.1-fold risk of cancer compared
with those without these risk factors after
adjustment for LDL cholesterol 2.80
mmol/l only, albuminuria only, and LDL
cholesterol 3.80 mmol/l. These risk as-
sociations remained signiﬁcant after ad-
justment for other covariates including
their possible nonlinear associations with
cancer. After exclusion of patients with
follow-up 2.5 years, the hazard ratio
(HR) increased from 2.77 (95% CI 1.78–
4.31) to 2.87 (1.54–5.34). The presence
of either albuminuria only or LDL choles-
terol 2.80 mmol/l only was not associ-
ated with increased cancer risk (Table 2).
RERI for interaction of LDL cholesterol
2.80mmol/lwithalbuminuriawas1.32
(0.28–2.37) and AP was 0.43 (0.18–
0.68) after adjustment for LDL 2.80
mmol/l only, albuminuria only, and LDL
cholesterol 3.80 mmol/l. Statistical sig-
niﬁcance persisted after adjustment for
other covariates including their possible
Table3—BiologicalinteractionsofLDLcholesterolwithalbuminuriaandcopresenceofthese
two risk factors with statin use for the risk of cancer in type 2 diabetes
Measures of biological interaction Estimate (95% CI)
Interaction models for albuminuria and low LDL cholesterol*
Model 1†
RERI 1.32 (0.28–2.37)‡
AP 0.43 (0.18–0.68)‡
S 2.75 (1.01–7.49)‡
Model 2§
RERI 1.01 (0.08–1.94)‡
AP 0.39 (0.11–0.68)‡
S 2.76 (0.78–9.71)
Model 3
RERI 1.05 (0.04–2.06)‡
AP 0.38 (0.09–0.66)‡
S 2.46 (0.85–7.09)
Interaction models for LDL cholesterol 2.80 mmol/l plus
albuminuria and nonuse of statins¶
Model 1†
RERI 4.07 (1.56–6.76)‡
AP 0.65 (0.42–0.89)‡
S 4.48 (1.26–15.91)‡
Model 2§
RERI 2.55 (0.57–4.52)‡
AP 0.58 (0.24–0.91)‡
S 3.90 (0.68–22.29)
Model 3#
RERI 2.87 (0.64–5.09)‡
AP 0.60 (0.29–0.90)‡
S 4.03 (0.82–19.78)
*The analysis was performed in 3,793 patients without use of statins. †Adjusted for LDL cholesterol 3.80
mmol/l. ‡Statistically signiﬁcant with RERI 0, AP  0, or S  1 indicating biological interaction. §Further
adjustedforage,sex,BMI,smokingstatus(currentsmokerplusex-smoker),drinkingstatus(currentdrinker
plus ex-drinker), duration of diabetes, A1C, systolic blood pressure, HDL cholesterol, triglycerides, eGFR,
and medications from enrollment to cancer, death, or censoring date, whichever came ﬁrst. Medications
includeACEIsorARBs,oralantidiabetesdrugs,insulin,ﬁbrates,andotherantihypertensivedrugs.Adjusted
for covariates listed in ‡, but restricted cubic spline functions were used for all the continuous covariates.
¶The analysis was performed in 3,793 patients without use of statins plus 1,483 patients who used statins
during follow-up. #Stratiﬁed Cox models on deciles of propensity scores were used to adjust for likelihood
of using statins during follow-up. The propensity score was calculated using a logistic regression procedure
with statin use as the dependent variable and the variables listed in Table 2, footnote ¶, as independent
variables.
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3). The cumulative incidence of cancer in
patients with both albuminuria and LDL
cholesterol 2.8 mmol/l was higher than
that for any other groups. Patients with
either albuminuria or LDL cholesterol
2.80 mmol/l (but not both) had similar
risksofcancerasthosewithoutexposures
to both risk factors (Fig. 1A).
Biological interaction between
copresence of low LDL cholesterol
plus albuminuria and nonuse of
statins for cancer risk
There was a signiﬁcant interaction be-
tweennonuseofstatinsandcopresenceof
LDL cholesterol 2.80 mmol/l and albu-
minuria for cancer risk. The RERI was
2.87 (95% CI 0.64–5.09) and AP was
0.60 (0.29–0.90) in a multivariable
spline Cox model analysis (Table 3). Sta-
tin nonusers who had LDL cholesterol
2.80 mmol/l and albumunuria had a
4.8-fold risk of cancer compared with all
others (HR 4.81, 95% CI 2.81–8.24). Pa-
tients with these two risk factors but
treated with statins during follow-up did
not have an increased cancer risk (0.64,
0.09–4.80) (Table 2).
Patients with LDL cholesterol 2.80
mmol/l and albuminuria but never
treated with statins had the highest inci-
dence of cancer, followed by statin non-
users without copresence of the two risk
factors. Patients treated with statins with
orwithoutcopresenceoflowLDLcholes-
terol and albuminuria had the lowest risk
of cancer (Fig. 1B). After adjustment for
thecovariateslistedinmodel3ofTable2,
the HR of cancer of statins nonusers who
had copresence of low LDL cholesterol
and albuminuria versus statin users with
or without copresence of both risk factors
was as high as 4.94 (95% CI 2.92–8.37,
P  0.0001).
Sensitivity analysis
We included 827 patients who used
statins at baseline in the cohort and applied
the adjusting analysis scheme of model 3
(Table 2). The interaction between LDL
cholesterol 2.80 mmol/l and albumin-
uria remained signiﬁcant (RERI 0.78,
95% CI 0.03–1.53; AP 0.35, 0.08–0.63).
The interaction between copresence of
LDL cholesterol 2.80 mmol/l plus albu-
minuria and nonuse of statin were also
signiﬁcant (RERI 1.95, 0.49–3.41; AP
0.51, 0.24–0.79).
CONCLUSIONS — In this prospec-
tive analysis, we detected an interaction
between LDL cholesterol 2.80 mmol/l
and albuminuria for cancer in type 2 dia-
betes, suggesting that copresence of both
risk factors confers an increased cancer
risk, more than simple summation of
the risks attributable to low LDL choles-
terol and albuminuria occurring in isola-
tion. Because the increased cancer risk
was not observed in patients with either
one of the abnormalities, our ﬁndings
Figure 1—Cumulative incidence of cancer stratiﬁed by albuminuria, LDL cholesterol 2.80
mmol/landstatusofstatinuseintype2diabetes.Awasderivedfrom3,793type2diabeticpatients
without use of statins (log-rank test, P  0.0001): a, patients without either albuminuria or LDL
cholesterol 2.80 mmol/l; b, patients with albuminuria only; c, patients with LDL cholesterol
2.80 mmol/l only; and d, patients with the copresence of LDL cholesterol 2.80 mmol/l and
albuminuria.Bwasderivedfrom3,793patientswithoutuseofstatinsplus1,483patientswhoused
statins during follow-up (log-rank test, P  0.0001): A, statin users who did not have the copres-
ence of LDL cholesterol 2.80 mmol/l and albuminuria; B, statin nonusers who did not have the
copresence of LDL cholesterol 2.80 mmol/l and albuminuria; C, statin users who had the
copresence of LDL cholesterol 2.80 mmol/l and albuminuria; and D, statin nonusers who had
the copresence of LDL cholesterol 2.80 mmol/l and albuminuria.
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type 2 diabetic patients with low LDL
cholesterol was conditional on the pres-
ence of albuminuria. Furthermore, we
found a signiﬁcant interaction between
nonuse of statins and copresence of these
two risk markers, suggesting that use of
statinsmayconferthelargestriskreduction
for cancer in patients with copresence of
low LDL cholesterol and albuminuria than
in patients without.
In type 2 diabetes, albuminuria
strongly predicts cardiorenal complica-
tions (22) and may serve as a composite
marker of risk factors, including hyper-
tension, inﬂammation, hyperglycemia,
and obesity (7). Patients with type 2 dia-
betes, especially those of Asian origin,
have a high prevalence of albuminuria. In
a case series, 56% Asian type 2 diabetic
patients had albuminuria compared with
40%oftheirCaucasiancounterparts(23).
In our analysis, patients with both expo-
sures, i.e., LDL cholesterol 2.80 mmol/l
and albuminuria, were more likely to
havealongerdiabetesduration,poorgly-
cemic control, and renal dysfunction
anduseinsulin(datanotshown).Taken
together, our ﬁndings suggest that
dysregulation of lipid and glucose me-
tabolism may interact with renal dys-
function to increase risk of cancer in
type 2 diabetes.
In our previous analysis, we hypoth-
esized that in type 2 diabetes, low LDL
cholesterol may upregulate the activity or
responsiveness of the mevalonate path-
way, which leads to lipid synthesis, and
theupregulatedmevalonatepathwaymay
be responsible for the increased risk of
cancer (5). Based on results from this
analysis, it is plausible that low LDL cho-
lesterol in the presence of albuminuria
mayincreasecancerriskbyup-regulating
the mevalonate pathway. Against this
background, statins reduce LDL choles-
terol by inhibiting hydroxymethylglu-
taryl-CoA reductase, the rate-limiting
enzyme of lipid synthesis, and thus
downregulate the mevalonate pathway.
Inkeepingwiththismechanismofaction,
we also found that statins attenuated the
elevated risk of cancer in patients with
copresence of low LDL cholesterol and
albuminuria.
Apart from generating new hypothe-
ses for basic scientists to investigate the
molecular mechanisms underlying the
risk association between cancer and type
2 diabetes, our ﬁndings have important
clinical implications: 1) because the risk
association of cancer with low LDL cho-
lesterol is dependent on albuminuria, it is
plausible that measures that reduce albu-
minuria,suchascontrolofhyperglycemia
andhypertension,mayreducecancerrisk
in type 2 diabetes; 2) albuminuria can be
usedtostratifycancerriskinpatientswith
low LDL cholesterol; and 3) use of statins
in patients with low LDL cholesterol and
albuminuria may reduce cancer risk.
Ontheotherhand,ourstudyhassev-
eral limitations. First, we used results
from a single urine and blood sample col-
lected during a comprehensive assess-
ment to stratify patients by albuminuria
status and LDL cholesterol levels. These
patients were managed in different clinics
and repeat data for LDL cholesterol and
albuminuria were not systematically col-
lected. Second, principle discharge diag-
noses were used to identify cancer cases
and a small number of cancer events
might have been missed. Third, the cohort
was mainly clinic-based, albeit the overall
clinical proﬁle was comparable to many
community-based cohorts (11). Fourth,
our analysis is a hypothesis-generating ex-
plorationandtheﬁndingswillneedreplica-
tion in independent cohorts.
Inconclusion,inaprospectivecohort
of Chinese patients with type 2 diabetes,
we detected a signiﬁcant biological inter-
action between low LDL cholesterol and
albuminuria for cancer. The association
between cancer and copresence of both
riskfactorswasattenuatedinthepresence
of statin treatment. Independent replica-
tion and experimental studies are needed
to conﬁrm these ﬁndings and elucidate
the underlying mechanism that will shed
lightonthepreventionofcancerintype2
diabetes.
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